FDA approval based on Phase III program demonstrating up to 51% reduction in asthma exacerbations, significant improvement in lung function and a 75% reduction in daily oral steroid use
{iframe}https://seekingalpha.com/pr/17002715-fasenra-benralizumab-receives-us-fda-approval-severe-eosinophilic-asthma{/iframe}